Sankhala, K. K., Chiorean, E. G., Armstrong, A. J., Borad, M. J., Traynor, A. M., Gadgeel, S. M., … Burris, H. (2010). Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology, 28(15_suppl), e13527–e13527. https://doi.org/10.1200/jco.2010.28.15_suppl.e13527

Sankhala, K. K., E. G. Chiorean, A. J. Armstrong, M. J. Borad, A. M. Traynor, S. M. Gadgeel, V. K. Langmuir, C. Eng, S. Kroll, and H. Burris. “Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): e13527–e13527. https://doi.org/10.1200/jco.2010.28.15_suppl.e13527.

Sankhala KK, Chiorean EG, Armstrong AJ, Borad MJ, Traynor AM, Gadgeel SM, et al. Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 2010 May 20;28(15_suppl):e13527–e13527.

Sankhala, K. K., et al. “Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC).” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. e13527–e13527. Crossref, doi:10.1200/jco.2010.28.15_suppl.e13527.

Sankhala KK, Chiorean EG, Armstrong AJ, Borad MJ, Traynor AM, Gadgeel SM, Langmuir VK, Eng C, Kroll S, Burris H. Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):e13527–e13527.